Bio-Techne Corporation (NASDAQ:TECH) has experienced significant financial and strategic activities in the recent past. These include adjusted
price target, decreased earnings per share (EPS), increased dividends, and Q4 2024 earnings. The company's investment in
Spear Bio is noteworthy, as is highlighted top-line biomarker data from partner
Regulus Therapeutics. The company has also engaged in several partnerships, notably with
Nikon Instruments Inc. and
Novomol-Dx. In terms of rewards, Bio-Techne has been recognized with CiteAb's ELISA Kit Supplier of the Year and Spatial Biology Innovation Awards. Drafting a legal bylaw, the company has filed a patent infringement lawsuit against Molecular Instruments. In corporate governance,
Kim Kelderman has been appointed as the new Chief Executive Officer. Significant stakeholder activities have occurred, with several major investment firms increasing their holdings, while others reduced their stake. To boost its operations, Bio-Techne has acquired Lunaphore and announced the acquisition of Asuragen. Recently, the company ended its collaboration program with Akoya. As an industry leader, Bio-Techne has presented at various investor conferences showcasing its growth strategy and advancements.
Bio-Techne Corp TECH News Analytics from Wed, 03 Mar 2021 08:00:00 GMT to Sun, 11 Aug 2024 10:59:15 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor 3
